The pancreatitis warning on Foundayo™

Confirmed cases in the trials

Section 6.1 reports pancreatitis differently from common reactions. Instead of a percentage of people, it counts cases confirmed by adjudication, meaning each suspected case went through a formal review before it was counted, and expresses them per 100 years of exposure, which adjusts for how long people actually took the medicine ^[1]. The pool is Trials 1 and 2, the 72-week ATTAIN-1 and ATTAIN-2 weight studies.

The Medication Guide lists pancreatitis among the serious side effects ^[2]. The European medicines committee adopted a positive opinion on 15 October 2026, but there is no EMA product information yet, and Health Canada has no Foundayo™ entry, so the US label is the only official document with figures ^[3][4].

How to read a rate per 100 years

A rate of 0.14 per 100 years of exposure means that if 100 people took Foundayo™ for a year, the expected number of confirmed pancreatitis cases would be well under one. With 3,155 people on the tablet and 1,576 on placebo, the absolute numbers are too small to say much about dose or timing, and the label does not try ^[1].

What the figures do show is a higher rate on treatment than on placebo, consistent with the label’s statement that acute pancreatitis has been reported with Foundayo™ ^[1].

Serious cases in the trial registries

The ATTAIN registries list every serious adverse event, whatever its frequency ^[5][6]. These are investigators’ reports, not the adjudicated count, and one person could carry more than one term. Even so, the totals line up with the label: six entries on orforglipron and one on placebo across the two trials. The registry gives no cause for any case.

What a handful of cases can and cannot say

• With one or two cases per group, no dose pattern can be read. Cases appeared on the 12 mg and 36 mg trial doses, which in ATTAIN correspond to Foundayo™ 9 and 17.2 mg, and none on 6 mg ^[1][5][6].
• The registry term obstructive pancreatitis points to a blockage, but the registry does not say what it was. NIDDK names gallstones stuck in a bile or pancreatic duct as the most common cause of acute pancreatitis ^[10].
• A relapsing case is a repeat episode; NIDDK notes that repeated acute attacks can lead to chronic pancreatitis ^[9].
• In ACHIEVE-3, one case occurred on each medicine, consistent with the label’s description of pancreatitis as a GLP-1 class concern ^[1][7].

What a network meta-analysis adds

Hageen and colleagues pooled randomised trials of orforglipron in a 2026 network meta-analysis, a method that compares several doses and placebo across trials at once ^[8]. They reported that no dose increased pancreatitis risk to a statistically significant degree, and that doses of 12 mg and above raised lipase and pancreatic amylase without a corresponding rise in clinical events ^[8].

Its limits matter. The analysis covered 26 weeks and included dose levels up to 45 mg that are not Foundayo™ strengths. Pancreatitis is so rare that a non-significant result means the trials could not show a difference, not that a risk has been ruled out. It does not replace the label’s adjudicated 72-week figures.

Enzyme rises on blood tests

On average, pancreatic amylase rose by 16% to 20% and lipase by 26% to 31% from baseline on Foundayo™, compared with 3% and 4% on placebo ^[1]. Section 6.1 states that the clinical significance of these rises is unknown when there are no other signs or symptoms of pancreatitis ^[1]. In the ATTAIN-2 registry, “lipase increased” was itself logged as an adverse event in 2.4% to 5.6% on orforglipron and 3.3% on placebo ^[6].

NIDDK explains that doctors diagnose pancreatitis by combining the history and examination with blood tests, including amylase and lipase, and imaging such as ultrasound or CT ^[11]. A raised enzyme result on its own therefore does not establish pancreatitis; it is something a clinician reads together with symptoms.

The warning in section 5.2

Section 5.2 asks clinicians to watch carefully for signs of acute pancreatitis after Foundayo™ is started. It notes that fatal and non-fatal hemorrhagic or necrotizing pancreatitis, the most severe forms, have been seen with GLP-1 receptor agonists as a class, and section 6.2 lists these among reports collected after approval, from a population of unknown size ^[1].

If pancreatitis is suspected, the label says to discontinue Foundayo™ and begin appropriate management. Section 17 asks prescribers to explain the symptoms and to tell patients to stop the tablet promptly and contact them ^[1]. The Medication Guide puts the same rule in plain words: if belly pain is severe and persistent, whether or not you feel sick or vomit, and especially if it reaches your back, the tablet is stopped and the provider called at once ^[2].

Why it might happen, and what else causes it

Supported by the label: acute pancreatitis has been reported with Foundayo™, and severe forms have been seen across the GLP-1 class (sections 5.2 and 6.2) ^[1]. The label describes no mechanism.

Plausible but not measured: section 5.8 reports gallstones in 1% on orforglipron against 0.7% on placebo and links gallbladder events to weight loss ^[1], and NIDDK names gallstones as the leading cause of acute pancreatitis ^[10]. The label does not connect the two for orforglipron, and no source reviewed here has measured that path.

General causes: NIDDK lists gallstones, heavy alcohol use, genetic disorders of the pancreas and some medicines as the most common causes, with high blood fats, high blood calcium, infections, abdominal injury, pancreatic cancer and the ERCP procedure among others ^[10]. Diabetes, obesity, smoking, a family history of pancreatitis and a personal or family history of gallstones also raise the likelihood ^[9].

Common stomach pain versus this warning

Ordinary abdominal pain is far more frequent on Foundayo™ than pancreatitis: Table 1 reports it in 13% to 14% of treated adults against 7% on placebo ^[1]. The label’s description of pancreatitis centres on how the pain behaves, not just where it is. What points towards the warning is pain that is severe or keeps going, especially if it reaches the back, not an ache that comes and goes after meals. NIDDK adds that people with acute pancreatitis usually look and feel seriously ill ^[10].

Before starting, and after an episode

The prescribing information has no separate statement about people who have had pancreatitis before, and it does not recommend routine enzyme testing ^[1]. The Medication Guide does ask you to tell your provider beforehand if you have or have had problems with your pancreas ^[2]. The label also does not describe restarting the tablet after an episode; that decision belongs to the treating team.

NIDDK says treatment of acute pancreatitis can include a hospital stay with fluids into a vein and pain relief, and gallbladder surgery when gallstones are the cause ^[12]. For people who have had pancreatitis, it strongly advises stopping alcohol and smoking, and it notes that a healthy weight lowers the chance of gallstones ^[12]. None of this is self-care for suspected pancreatitis: the instruction to stop the tablet and seek care comes first ^[2].

Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.